Pfizer: Neue Daten – Aktie steigt
Der amerikanische Pharma-Riese setzt große Stücke aus Abrysvo, sein Vakzin gegen das Respiratorische Synzytialvirus (RSV). Doch Pfizer ist nicht allein.…
25,105€
1,05%
Echtzeit-Aktienkurs Pfizer Inc.
Bid:
Ask:
Nachrichten zur Pfizer Inc. Aktie
Pfizer: Neue Daten – Aktie steigt
Der amerikanische Pharma-Riese setzt große Stücke aus Abrysvo, sein Vakzin gegen das Respiratorische Synzytialvirus (RSV). Doch Pfizer ist nicht allein.…
Opening Bell: US-Börsen kommen nicht vom Fleck; Gold, Silber, First Solar, Apple, Alphabet, Pfizer im Fokus
Auch am Dienstag deutet sich an der Wall Street zunächst wenig Bewegung an. Der Broker IG taxierte den Dow Jones…
Tilray, Coinbase. Maxeon and Tesla fall premarket; Pfizer and BP rise By Investing.com
Tilray, Coinbase. Maxeon and Tesla fall premarket; Pfizer and BP rise…
Pfizer RSV shot meets goals in trial of high-risk adults under age 60
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in…
Pfizer RSV shot meets goals in trial of high-risk adults under age 60 By Reuters
Pfizer RSV shot meets goals in trial of high-risk adults under age 60…
Pfizers RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above…
Pfizer: AbbVie, Bristol-Myers, Eli Lilly, Johnson & Johnson, Takeda - Die Konkurrenz ist enorm - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…
Pfizer: Enorme Konkurrenz
Mitte Dezember 2021 hat Pfizer die milliardenschwere Übernahme von Arena Pharmaceuticals verkündet und sich somit den Zugriff auf die Substanz…
Pfizer: Enorme Konkurrenz
Mitte Dezember 2021 hat Pfizer die milliardenschwere Übernahme von Arena Pharmaceuticals verkündet und sich somit den Zugriff auf die Substanz…
Better Recovery Story Buy: Pfizer vs Moderna
…
Better Recovery Story Buy: Pfizer vs Moderna @themotleyfool #stocks $PFE $MRNA
Pfizer and Moderna each have slipped about 30% over the past year.…
Better Recovery Story Buy: Pfizer vs Moderna
Pfizer and Moderna each have slipped about 30% over the past year.…
Prediction: Pfizer Wont Acquire Viking Therapeutics. Heres Why.
Viking Therapeutics may be the next company to enter the red-hot weight loss space.…
Prediction: Pfizer Wont Acquire Viking Therapeutics. Heres Why.
…
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran
The current therapeutic landscape of hemophilia B in the 7MM is driven by several approved therapies. The hemophilia B market…
Astra, Pfizer Boost China Bets Despite US Drive to Decouple
The chief executive officers of AstraZeneca Plc and Pfizer Inc. pledged to support expansion of China’s biopharmaceutical industry, even as…
Pfizer: Diesen Rückzugsbereich müssen Anleger kennen! Chartanalyse
Düsseldorf (www.aktiencheck.de) - Pfizer-Chartanalyse von HSBC Trinkaus & Burkhardt:
Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse…
Will Pfizer Be a Trillion-Dollar Stock by 2035?
…
Will Pfizer Be a Trillion-Dollar Stock by 2035?
A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.…
Will Pfizer Be a Trillion-Dollar Stock by 2035? @themotleyfool #stocks $PFE
A market cap of $1 trillion for Pfizer over the next 11 or so years? Possible, but not probable.…
Argus downgrades Pfizer, lowers earnings estimates on near-term headwinds By Investing.com
Argus downgrades Pfizer, lowers earnings estimates on near-term headwinds…
Pfizer: Kurzfristiger Gegenwind - Die Aktie abgestuft - Aktienanalyse
New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Argus Research:
Die Analysten von Argus Research stufen die Aktie von Pfizer Inc. (ISIN: US7170811035,…
Pfizer: Guggenheim überarbeitet Modelle für Large-Cap-Biopharmazieunternehmen - Aktienanalyse
New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Guggenheim Securities:
Die Analysten von Guggenheim Securities senken in einer aktuellen Aktienanalyse ihr Kursziel für…
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower…
Community Oncology Services Global Market Report 2024
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Report 2024" report has been…
Is Pfizer the Best Dividend Stock for You?
…
Is Pfizer the Best Dividend Stock for You?
Pfizers stock is cheap, and it pays an incredibly high yield right now.…
Is Pfizer the Best Dividend Stock for You? @themotleyfool #stocks $PFE
Pfizers stock is cheap, and it pays an incredibly high yield right now.…
Gewinneinbruch bei Biontech nach Pandemieende - Erstes Krebsmittel 2026 erwartet
Frankfurt (Reuters) - Das Mainzer Biotechunternehmen Biontech hat im vergangenen Jahr den Nachfrageeinbruch bei Corona-Impfstoffen zu spüren bekommen.
Der Umsatz…
Pfizer sells £3B of shares in Haleon
…
Pfizer offloads $3.9 billion stake in Sensodyne-maker Haleon
…
Pfizer offloads $3.9 billion stake in Sensodyne-maker Haleon By Reuters
Pfizer offloads $3.9 billion stake in Sensodyne-maker Haleon…
Pfizer upsizes Haleon stake sale
Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping…
Pfizer Sells £3 Billion of Shares in Sensodyne Maker Haleon
Pfizer Inc. has sold over £3 billion ($3.8 billion) of shares in Haleon Plc, the first step by the UK…
Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%
Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its…
Pfizer Is Selling a Chunk of Its Haleon Stock. It’s a $3 Billion Windfall.
…
5 Reasons Why Buying This 6%-Yielding Dividend Stock Could Be a Brilliant Move @themotleyfool #stocks $PFE
Pfizer just might be one of the biggest comeback stories of the second half of this decade.…
Pfizer to trim its Haleon stake to 24% By Investing.com
Pfizer to trim its Haleon stake to 24%…
Pfizer reduziert Haleon-Anteil auf 24 Prozent
Von Elena Vardon BARCELONA (Dow Jones)--Pfizer will rund 630 Millionen seiner Haleon-Aktien auf den Markt werfen und dadurch seine…
Pfizer to sell down stake in Haleon
Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising…
Pfizer to sell down stake in Haleon
Pfizer Inc (NYSE:PFE, ETR:PFE) has confirmed it will sell a large chunk of its stake in Haleon PLC (LSE:HLN, NYSE:HLN), raising…
Pfizer to cut stake in Sensodyne toothpaste-maker Haleon to 24%
…
Consumer healthcare giant Haleon says Pfizer to cut stake to 24% By Reuters
Consumer healthcare giant Haleon says Pfizer to cut stake to 24%…
Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns
…
Is Pfizer Stock a Millionaire Maker?
A couple of years ago, Pfizers shares may have seemed like a sure thing. That may not be the case…
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
…
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market? @themotleyfool #stocks $PFE $LLY $NVO $VKTX $ALT
Viking Therapeutics just might be an attractive acquisition target for Pfizer.…
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Viking Therapeutics just might be an attractive acquisition target for Pfizer.…